Eocene Ltd. (GLMD) News
Track canonical SquawkNews coverage tagged to GLMD, Eocene Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Galmed rebrands as Eocene Ltd., switching ticker to EOCN
Galmed Pharmaceuticals announced a corporate rebranding to Eocene Ltd., including a change in its ticker symbol to reflect the new platform.
GEOPOLITICS | Sep 09, 2026, 11:30 AM UTC
L
Galmed Pharmaceuticals switches ticker to EOCN
Galmed Pharmaceuticals is changing its ticker symbol to EOCN.
EQUITY | Sep 09, 2026, 11:30 AM UTC
L
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
FORECAST CHANGESRECOMMENDATIONSThis summary was machine generated from LSEG data September 4 at 01:15 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, conta
EARNINGS | Sep 04, 2026, 01:16 AM UTC
M
Galmed reports first-in-human proof-of-concept results for Colospan technology
Galmed announces successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology.
EQUITY | Aug 19, 2026, 11:01 AM UTC
M
Galmed announces first-in-human proof-of-concept study results for Colospan technology
Galmed says Colospan's novel intraoperative tissue assessment technology produced successful first-in-human proof-of-concept clinical study results.
EQUITY | Aug 19, 2026, 11:00 AM UTC
L
CISS, GLMD announce reverse stock splits Wednesday
CISS plans a 1-for-40 reverse split and GLMD plans a 1-for-8 reverse split for Wednesday Aug. 19.
EQUITY | Aug 19, 2026, 09:03 AM UTC
L
CISS, NRDY and GLMD announce Aug 19 reverse stock splits
CISS will execute a 1-for-40 reverse split on Aug 19, while NRDY plans a 1-for-15 reverse split and GLMD a 1-for-8 reverse split.
REGULATION | Aug 18, 2026, 08:35 PM UTC
M
CISS, NRDY, and GLMD announce reverse stock splits Aug 19
CISS is scheduled for a 1-for-40 reverse split, NRDY for a 1-for-15 reverse split, and GLMD for a 1-for-8 reverse split on Wednesday Aug 19.
REGULATION | Aug 18, 2026, 07:09 PM UTC
H
Galmed (GLMD) reports aramchol 3–4x cell death vs enzalutamide alone
Galmed announces first results from prostate oncology studies showing aramchol delivers a 3–4 fold increase in cell death versus enzalutamide (XTANDI®) alone in prostate cancer models.
EQUITY | Aug 17, 2026, 01:15 PM UTC
M
Galmed Pharmaceuticals Terminates License Agreement
Galmed terminates license agreement
EQUITY | Jul 29, 2026, 08:53 PM UTC
L
GLMD GLMD - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibito
GLMD GLMD - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
EQUITY | Jul 28, 2026, 11:02 AM UTC
H
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro
EARNINGS | Jul 21, 2026, 09:11 AM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC
L
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
EQUITY | Jul 01, 2026, 07:59 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
GLMD Increases Cash Portion
Galmed agrees to increase cash portion of purchase price for Colospan by $800K
EQUITY | Jun 22, 2026, 11:35 AM UTC
M
GLMD Restructures Acquisition Terms
Galmed Pharmaceuticals Ltd. restructures acquisition terms for Colospan Ltd., prioritizing CG-100 European commercialization and shareholder value protection.
EQUITY | Jun 22, 2026, 11:03 AM UTC